⌕
Beam Therapeutics · BEAM · Nasdaq
Tenet 61 · Solid
Compare
$20.65−1.38%At closeTenet 61 · Solid
$20.65−0.29 (−1.38%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Beam Therapeutics (BEAM) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

46 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 63% below its peak, net margin −57.2%. Worth your attention in FY25: Share count (+54.0%) and Capex step-up ($14.9M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲120.0%
139.7
FY21→FY25CAGR +28.1%/yr
Net income ($M)▲78.8%
−80.0
FY21→FY25CAGR —
Free cash flow ($M)▼1.1%
−360.0
capex stepped upCAGR —
Diluted EPS▲82.3%
−0.81
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+54.0%

64.2mn → 98.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$14.9M

▲67% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

Returns vs FCF
n/m

$0.0M returned vs $−360.0M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)139.7Revenue0.0COGS−409.6R&D−113.8SG&A−383.7Op income303.7Tax & other−80.0Net income

-57¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -57.2% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
146,644.0139,743.063,518.0377,709.060,920.051,844.0▲120.0%+28.1%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A—A—A—A—A51,844.0——
Research & development
409,005.0409,618.0367,561.0437,381.0311,594.0387,087.0▲11.4%+1.4%
Selling, general & admin
130,174.0113,818.0111,525.0116,813.087,805.057,222.0▲2.1%+18.8%
Total operating expenses
539,152.0523,436.0479,086.0554,194.0399,399.0444,309.0▲9.3%+4.2%
Operating incomefeeds ROC rank
−392,535.0−383,693.0−415,568.0−176,485.0−338,479.0−392,465.0▲7.7%—
Other income, net
284,181.0303,701.038,865.045,324.078,301.021,827.0——
Pretax income
−108,354.0−79,992.0−376,703.0−131,161.0−260,178.0−370,638.0▲78.8%—
Income tax
—0.039.01,366.03,410.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−108,354.0−79,992.0−376,742.0−132,527.0−289,088.0−370,638.0▲78.8%—
Per share
Diluted EPSbuyback-sensitive
−0.85−0.81−4.58−1.72−4.13−5.77▲82.3%—
Diluted shares (mn)
104.7098.9182.3177.1570.0264.23▲20.2%+11.4%
Margins
Gross margin
—A—A—A—A—A100.0%——
Operating margin
−267.7%−274.6%−654.3%−46.7%−555.6%−757.0%▲379.7pp+482.4pp
Net margin10th pct in Healthcare
−73.9%−57.2%−593.1%−35.1%−474.5%−714.9%▲535.9pp+657.7pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Beam Therapeutics' revenue last fiscal year?

Beam Therapeutics reported revenue of $139.7M in fiscal 2025, up 120.0% from fiscal 2024.

What was Beam Therapeutics' net income?

Beam Therapeutics reported net income of −$80.0M in fiscal 2025, a net margin of −57.2%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.